Sandoz Ups Biosimilar Game With Alteogen Subcutaneous Tech Deal
Alteogen Comments Suggests Deal Worth Up To $145m
Sandoz is eyeing development of up to three subcutaneous formulation biosimilars, which offer greater benefits to both patients and healthcare providers, via a technology agreement with Korean firm Alteogen.
